Vanguard Capital Management
NERV icon

Vanguard Capital Management’s Minerva Neurosciences NERV Stock Holding History

Vanguard Capital Management’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10.5M Buy
1,892,807
+46,976
+3% +$255K ﹤0.01% 2783
2026
Q1 		$11.1M Buy
+1,845,831
New +$10.6M ﹤0.01% 2678

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ABG
Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $643M AUM 343.43% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM

Vanguard Capital Management's NERV Position: Q2 2026 in Review

Vanguard Capital Management increased its Minerva Neurosciences (NERV) stake by 2.5% in Q2 2026, buying an estimated $255K and bringing the position to 1,892,807 shares worth $10.5M. The position accounts for ﹤0.01% of the portfolio, ranked #2783.

Vanguard Capital Management first reported a position in NERV in Q1 2026 and has held it in 2 quarters since. The position peaked at $11.1M in Q1 2026. 60 funds tracked by Wall St. Rank hold NERV as of Q2 2026.

  • Vanguard Capital Management held 1,892,807 shares of Minerva Neurosciences worth $10.5M as of Q2 2026.
  • Vanguard Capital Management bought 46,976 Minerva Neurosciences shares in Q2 2026, an estimated $255K.
  • Minerva Neurosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2783 holding.
  • Vanguard Capital Management first reported a position in Minerva Neurosciences in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Minerva Neurosciences position peaked at $11.1M in Q1 2026.
  • 60 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.